People with amyotrophic lateral sclerosis (ALS) who also have diabetes tend to lose the ability to walk faster than non-diabetic patients, according to a study from Japan. The findings underscore the importance of supportive mobility care for diabetic ALS patients, scientists said in the study, “Factors…
EKZ-102, Eikonizo Therapeutics‘s experimental oral therapy for amyotrophic lateral sclerosis (ALS), is on track to enter early clinical testing in 2026, according to an announcement from the company. EKZ-102 is designed to block the activity of a protein called HDAC6. A team led by scientists at Eikonizo…
Life Time will host a nationwide fitness event Oct. 25 to raise funds for ALS research and children’s health. The annual GO90: Move with Meaning challenge will take place at Life Time locations nationwide on Oct. 25 at 9 a.m. local time. Life Time members and nonmembers are…
People with a history of traumatic brain injury (TBI) have a nearly three times higher risk of developing amyotrophic lateral sclerosis (ALS) than those who have not experienced a head injury, a new study found. However, the risk is highest in the two years following a TBI and decreases…
Using seven clinical measures that are fairly easy to assess, researchers have developed a machine learning model to help predict mortality in people with amyotrophic lateral sclerosis (ALS), according to a study. The model, which was trained on data from more than 1,900 patients, may aid clinicians and families…
A pivotal Phase 3 clinical trial testing the oral therapy pridopidine in people with amyotrophic lateral sclerosis (ALS) is expected to start in January, following promising results seen in the HEALEY ALS platform trial. Pending regulatory clearance, enrollment will begin at ALS treatment centers in the U.S., Canada,…
The Canadian amyotrophic lateral sclerosis (ALS) community is calling for the country’s government to invest CA$50 million (about $36 million) over the next five years to support the Canadian Collaboration to Cure ALS. Advocates, including people with ALS, caregivers, clinicians, and researchers, gathered at Parliament Hill on Oct. 2…
In a new study by a team of U.S. scientists, a group of inflammatory immune cells was found to mistakenly target the C9ORF72 protein in nerve cells in people with amyotrophic lateral sclerosis (ALS) — demonstrating that ALS may be an autoimmune disease. The findings, by researchers at the…
For years, researchers have been chasing a so-called silver bullet compound that could effectively treat anyone with amyotrophic lateral sclerosis (ALS). Hande Ozdinler, an associate professor of neurology at Northwestern University, thinks that this approach should be reassessed and a different, more nuanced view of ALS treatment should…
FGF21, a hormone that helps cells regulate energy use and respond to stress, may protect muscles and nerve cells from damage related to amyotrophic lateral sclerosis (ALS), slowing disease progression. A study found ALS patients had significantly higher levels of FGF21 in their blood and muscles than healthy controls,…
